Irbesartan/Hctz 25 mg (Hydrochlorothiazide TABLET) 25 MG

Irbesartan/HCTZ 25 mg tablets combine irbesartan and hydrochlorothiazide for blood pressure management. This dual-action medication is commonly used to treat hypertension.

Strength

25 MG

Pack Size

30/500

Manufacturer / TM Owner

SANIS HEALTH INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Irbesartan/HCTZ 25 mg tablets are primarily used for managing high blood pressure. The combination of irbesartan, an angiotensin II receptor blocker, and hydrochlorothiazide, a diuretic, works to lower blood pressure by relaxing blood vessels and reducing fluid retention. This medication is often prescribed for individuals who require both types of treatment to achieve optimal blood pressure control.

Side Effects

Common effects of Irbesartan/HCTZ 25 mg tablets may include dizziness, fatigue, and mild nausea. Some users might experience dehydration or electrolyte imbalances due to the diuretic component. It's important to stay hydrated and monitor for any unusual symptoms while taking this medication.

Precautions & Warnings

Irbesartan/HCTZ 25 mg tablets should be handled with care, especially for individuals with kidney or liver issues. Regular monitoring of blood pressure and electrolyte levels is recommended. Avoid sudden changes in dosage without consulting a healthcare provider.

Avoid Interactions

Irbesartan/HCTZ 25 mg tablets may interact with other blood pressure medications, NSAIDs, and certain diuretics. Alcohol consumption should be limited, as it can enhance the effects of the medication. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.

Frequently Asked Questions

Irbesartan/HCTZ 25 mg tablets are used to manage high blood pressure by combining the effects of irbesartan and hydrochlorothiazide.

Irbesartan/HCTZ 25 mg tablets are typically taken orally, usually once daily, as directed by a healthcare provider.

Common side effects may include dizziness, fatigue, and mild nausea. Stay hydrated and monitor for any unusual symptoms.

It is advisable to limit alcohol consumption while taking Irbesartan/HCTZ 25 mg, as it can enhance the medication's effects.

Individuals with severe kidney or liver issues should exercise caution and consult a healthcare provider before taking Irbesartan/HCTZ 25 mg tablets.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.